Belle Mead, NJ, United States of America

Hao Zhang

This inventor holds 35 USPTO granted patents and 4 published patent applications and 17 EPO patents, primarily in LPA Antagonists. Top assignees: Bristol-Myers Squibb Compnay, Bristol Meyers Squibb Company, Syngene International Limited. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hao Zhang. Retrieved from https://idiyas.com/inventor/hao-zhang-cxzkqe8f

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 35 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.6

ph-index = 8

Forward Citations = 276(Granted Patents)


Location History:

  • Golden, CO (US) (2022)
  • Flushing, NY (US) (2022)
  • Belle Mead, NJ (US) (2002 - 2023)

Company Filing History:


Years Active: 2002-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
LPA Antagonists
Triazole Compounds
Isoxazole Compounds
GPR120 Modulators
Carbamoyl Derivatives
Cyclohexyl Acids
Antidiabetic Agents
Antiobesity Agents
Bicyclo Acids
Curvable LED Lighting
Spherical Image Registration
Heterocyclic Derivatives
35 patents (USPTO):Explore Patents

Title: Hao Zhang: A Prolific Inventor in LPA Receptor Inhibitors

Introduction:

In the realm of pharmaceutical innovations, Hao Zhang, based in Belle Mead, NJ, is a renowned inventor with a remarkable portfolio of patents. With a focus on the development of compounds known as LPA (Lysophosphatidic acid) receptor inhibitors, Zhang has made significant contributions to the field.

Latest Patents:

Zhang's latest patents demonstrate his expertise in LPA receptor inhibitors. One of his recent inventions is the "Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists." This patent introduces a novel class of compounds (Formula I), selective LPA receptor inhibitors, which hold promising potential for various therapeutic applications.

Additionally, Zhang's patent for "Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists" extends his innovative work in this area. This invention, represented by compounds of Formula I, further emphasizes the development of selective LPA receptor inhibitors for potential use in pharmaceutical applications.

Career Highlights:

Over the course of his career, Zhang has accumulated an impressive total of 30 patents. His dedication to research and development has firmly established him as a notable figure in the field of pharmaceutical innovations. Zhang's patents highlight his continuous pursuit of novel LPA receptor inhibitors and his ability to bring groundbreaking concepts to life.

Collaborations:

Throughout his professional journey, Zhang has collaborated with esteemed colleagues, Yan Shi and Peter Tai Wah Cheng, on various projects. These collaborations have further enriched his research endeavors and established a collaborative network within the field. By working alongside individuals who share his passion for innovation, Zhang has fostered an environment conducive to driving scientific advancements.

Conclusion:

Hao Zhang's expertise in the development of selective LPA receptor inhibitors has propelled him to the forefront of pharmaceutical innovations. With an impressive patent portfolio and collaborations with esteemed researchers, Zhang continues to push the boundaries of scientific discovery. As the global healthcare industry evolves, the contributions of inventors like Hao Zhang become vital, offering new possibilities and advancements in the treatment of various diseases and conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…